Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Open To User Fees To Support Oversight Of Internet Drug Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry continues to push for a universal symbol that links to FDA-regulated drug risk and benefit information from search engine results.

You may also be interested in...



Advertising Regulation Wiki? Industry Wants Authoritative But Frequently Updated FDA Guidance (And/Or Regs) On Internet Drug Promotion

It's up to FDA now to outline a "how-to" for drug makers when it comes to using the Internet and social media for drug promotion - with guidance, regulations or both. But drug makers made evident in comments on the agency's meeting last fall that FDA also must determine how to account for changing technologies

Advertising Regulation Wiki? Industry Wants Authoritative But Frequently Updated FDA Guidance (And/Or Regs) On Internet Drug Promotion

It's up to FDA now to outline a "how-to" for drug makers when it comes to using the Internet and social media for drug promotion - with guidance, regulations or both. But drug makers made evident in comments on the agency's meeting last fall that FDA also must determine how to account for changing technologies

FDA's Appropriations Outlook: More Purse, Emphasis On The Strings

Giving FDA more resources has vocal support on Capitol Hill, but so does changing the way the agency operates.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel